Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.10 and traded as low as $0.08. Nascent Biotech shares last traded at $0.08, with a volume of 24,599 shares changing hands.
Nascent Biotech Trading Down 8.0 %
The business’s 50-day simple moving average is $0.10 and its 200 day simple moving average is $0.13.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Featured Articles
- Five stocks we like better than Nascent Biotech
- Overbought Stocks Explained: Should You Trade Them?
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- How is Compound Interest Calculated?
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
